|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| Research and collaboration revenue | ||
| Operating expenses | ||
| Research and development | ||
| General and administrative | ||
| Impairment of right-of-use asset | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other (expense) income, net: | ||
| Interest income | ||
| Change in fair value of derivative tranche liability | ||
| Other expense | ||
| Total other (expense) income, net | ||
| Net loss | ||
| Other comprehensive income (loss) | ||
| Total comprehensive loss | ||
| Net loss per share attributable to common stockholders, basic, (in USD per share) | ||
| Net loss per share attributable to common stockholders, diluted, (in USD per share) | ||
| Weighted-average shares of common stock outstanding, basic, (in shares) | ||
| Weighted-average shares of common stock outstanding, diluted, (in shares) |
Loading...
